Evofem Biosciences, Inc.
EVFM · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.00 | -0.11 | -0.00 |
| FCF Yield | 23.22% | -257.65% | 1.05% | -252.16% |
| EV / EBITDA | 69.68 | -42.74 | 178.22 | -71.93 |
| Quality | ||||
| ROIC | 257.68% | 10.22% | -2.67% | 9.37% |
| Gross Margin | 0.00% | 84.35% | 56.80% | 78.72% |
| Cash Conversion Ratio | -0.21 | 1.64 | 0.59 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | -1.97% | 5.23% | -3.35% | 4.77% |
| Free Cash Flow Growth | 111.50% | -621.61% | 123.26% | -424.62% |
| Safety | ||||
| Net Debt / EBITDA | 68.16 | -41.72 | 81.84 | -70.45 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.40 | 0.16 | 0.96 |
| Cash Conversion Cycle | 0.00 | -1,145.91 | -2,087.18 | -744.19 |